Product-focused roadmap shows how MSC secretomes can become scalable, standardized, GMP-ready biotherapeutics.
Adipose-Derived Mesenchymal Stromal Cell Therapy Shows No Significant Benefit in Knee Osteoarthritis
Compared with an injection of saline placebo, a single intra-articular injection of autologous adipose-derived mesenchymal stromal cells showed no significant improvement in pain or function scores in ...
FDA fast tracks Wisconsin cell therapy using marrow stromal cells to treat dry mouth in Sjögren’s patients in a new clinical trial.
The US Food and Drug Administration (FDA) has approved remestemcel-L (Ryoncil, Mesoblast Ltd), an allogeneic bone marrow‒derived mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...
The stroma to tumor ratio potentially identifies higher risk bladder cancer tumors and might help guide immunotherapy. Bladder tumors with higher stromal content may have a more immunosuppressive ...
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results